Aurobindo Seeks To Boost India Business With Veritaz Acquisition
Indian Pharma Firm Has Paid INR1.71bn For Domestic Formulations Business
Executive Summary
Aurobindo is looking to grow its business in India by acquiring Veritaz’s domestic formulations operations in a $22.4m slump sale.
You may also be interested in...
Deal Watch: Jazz Breaks Into Immuno-Oncology Via Licensing Pact With Werewolf
AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.
What’s Next? Five Things To Look Out For In April
In the month ahead, Japanese firms are set to be hit with further price cuts to their generics, while Eagle Pharmaceuticals will throw off the restraints for its Pemfexy (pemetrexed) 505(b)(2) version of Eli Lilly’s Alimta.
Aurobindo Accelerates Biosimilars Efforts With Second Filing
Aurobindo has filed for its second oncology biosimilar with the EMA in January 2022, as the company remains on track to develop its biosimilars portfolio in both oncology and immunology segments. The company has also launched seven products, including four injectables, in its financial third quarter ended 31 December 2021.